What is peptide YY is a question that comes up as drug makers test PYY-based molecules alongside GLP-1 medicines such as semaglutide. The hormone was isolated from pig intestine in 1980. Human studies have since measured its effects on hunger and food intake.
Quick answer: Peptide YY is a natural hormone released by the intestine after meals. Its shortened form, PYY3-36, acts on Y2 receptors linked to the brain's feeding circuits. PYY is not an approved medicine. Long-acting PYY analogues remain investigational.
What is peptide YY, and is it a peptide?
Yes. Peptide YY is a peptide hormone, a short chain of amino acids that carries a signal through the blood. Vitrapep's guide to what peptides are covers the general category.
In 1980, Tatemoto and Mutt described a chemical method that detects peptides ending in a C-terminal amide. Applied to pig small intestine, it found several unknown peptide amides. The paper described two, PHI and PYY, and reported that PYY was related to pancreatic polypeptide (Tatemoto and Mutt, 1980).
In 1988, a Stanford-led team purified human PYY from colon tissue. It is 36 amino acids long and differs from pig PYY at only two positions (Tatemoto et al., 1988). The name comes from tyrosine, whose one-letter code is Y. Human PYY starts with tyrosine and ends with a tyrosine amide.
PYY belongs to a family with neuropeptide Y (NPY) and pancreatic polypeptide (PP). The three share a conserved, proline-rich starting sequence (Mentlein et al., 1993). Table 1 summarizes key facts.
What is peptide YY, and is it a peptide
| Feature | What the research reports | Source |
|---|---|---|
| Length in humans | 36 amino acids, ending in a tyrosine amide | Tatemoto et al., 1988 |
| Peptide family | Related to pancreatic polypeptide and NPY | Tatemoto and Mutt, 1980; Mentlein et al., 1993 |
| Source cell | Intestinal L cells, which also make GLP-1 | Habib et al., 2013 |
| Highest tissue levels | Lower gut, peaking in the rectum | Adrian et al., 1985 |
| Shortened form | PYY3-36, after DPP-4 removes the first two amino acids | Mentlein et al., 1993 |
| Receptor preference of PYY3-36 | Highly selective for Y2; did not bind Y1 in cell tests | Grandt et al., 1992 |
| FDA-approved products | None found | Drugs@FDA search, November 18, 2026 |
Where is PYY made in the body?
PYY is made in the gut lining, mostly toward its far end. A 1985 study found PYY only in the mucosal epithelium of human intestine, the layer that holds hormone-secreting cells (Adrian et al., 1985). Tissue levels were lowest in the duodenum and jejunum. They peaked in the rectum, at about 80 times the duodenal level. Fasting blood levels were low, then rose after food and stayed raised for several hours.
The cells that make PYY are L cells. A 2013 Cambridge study cultured cells from fresh human colon biopsies (Habib et al., 2013). GLP-1 and PYY sat in the same cells and the same secretory vesicles. The authors found no PYY cells that did not also produce GLP-1. Vitrapep's article on what GLP-1 is covers that partner hormone.
What is PYY3-36, and how does it differ from PYY1-36?
Full-length PYY is called PYY1-36. PYY3-36 lacks the first two amino acids, tyrosine and proline, so it is 34 amino acids long.
A 1992 German study found both forms in dog colon, with PYY3-36 about 40% of the total (Grandt et al., 1992). PYY3-36 did not bind Y1 receptors on a human cell line. It matched full-length PYY at inhibiting pancreatic secretion, which the authors attributed to Y2 receptors. They called PYY3-36 a highly selective Y2 agonist.
The trimming enzyme is dipeptidyl peptidase-4 (DPP-4). In a 1993 lab study, purified human DPP-4 cut tyrosine-proline from PYY and NPY with very high activity. Human serum made the same cut, and DPP-4 inhibitors blocked it (Mentlein et al., 1993).
DPP-4 cleavage inactivates GLP-1 and GIP. For PYY, the same cut instead yields a more Y2-selective form (Briere et al., 2026). Vitrapep's article on what GIP is covers the other incretin hormone.
How does PYY affect appetite?
Most appetite research involves PYY3-36. A 2002 Imperial College paper combined animal and human experiments (Batterham et al., 2002). In rats, PYY3-36 reduced food intake and weight gain. It reduced food intake in normal mice, but not in mice lacking the Y2 receptor.
In the arcuate nucleus, a feeding center in the hypothalamus, PYY3-36 inhibited NPY nerve terminals. That activated neighboring POMC neurons, part of the melanocortin system that helps regulate food intake. These are animal findings. In the human part of the study, infusions reproducing normal after-meal PYY3-36 levels reduced appetite. Food intake fell by 33% over 24 hours.
The rodent results proved hard to repeat. In 2004, a group of 42 researchers reported in Nature that they could not replicate them (Tschöp et al., 2004). They wrote that this called into question an anti-obesity approach based on giving PYY3-36.
What did human PYY studies measure?
Controlled human studies of PYY have mostly been short. Table 2 lists key ones.
In 2003, the Imperial group compared 12 obese and 12 lean volunteers in a double-blind, placebo-controlled crossover study (Batterham et al., 2003). At a buffet lunch two hours after PYY3-36 infusion, calorie intake was 30% lower in the obese group and 31% lower in the lean group. Obese volunteers had lower fasting PYY, and fasting levels correlated negatively with body mass index. The authors concluded that obese people were not resistant to PYY's effect.
A 2005 Swiss study tested graded PYY3-36 infusions against placebo in healthy men, double-blind (Degen et al., 2005). Food intake fell by up to 35%. The reduction was significant only at blood levels above those seen after normal meals. The authors concluded that PYY3-36's natural role in human satiety remained to be defined.
After Roux-en-Y gastric bypass, after-meal PYY and GLP-1 rose within 2 days (le Roux et al., 2007). Blocking gut hormone release brought appetite and food intake back. This design cannot separate PYY's role from GLP-1's.
What did human PYY studies measure
| Study | Design and population | Main finding | Evidence level |
|---|---|---|---|
| Batterham et al., 2003 | Double-blind, placebo-controlled crossover; 12 obese and 12 lean adults | Buffet calorie intake 30% lower (obese) and 31% lower (lean) | Human, single sessions |
| Degen et al., 2005 | Double-blind, placebo-controlled graded infusions; healthy men | Food intake down by up to 35%, only significant above normal after-meal levels | Human, single sessions |
| le Roux et al., 2007 | Gastric bypass patients | Blocking gut hormone release brought appetite back | Human, surgical setting |
| Gantz et al., 2007 | Randomized, double-blind, placebo-controlled; 133 adults with obesity; 12 weeks | No significant weight difference from placebo | Human, drug trial |
| Wulff et al., 2025 | Phase 2; 83 adults with obesity; analogue or placebo added to semaglutide; 16 weeks | 2.2 percentage points more weight loss than placebo | Human, Phase 2 |
| Briere et al., 2026 | Phase 1; 65 adults, some with type 2 diabetes on dulaglutide; single doses | Up to 2.58 kg more weight loss than dulaglutide alone | Human, Phase 1 |
Why did early PYY drug trials struggle?
Merck tested PYY3-36 for weight loss in a 2007 trial (Gantz et al., 2007). After a placebo run-in, 133 adults with obesity were randomized to placebo or one of two PYY3-36 doses for 12 weeks. All groups also followed a reduced-calorie diet and exercise.
Completion rates were 88% on placebo, 70% on the lower dose and 26% on the higher dose. The lower dose's weight difference from placebo, 0.9 kg, was not statistically significant. The authors concluded the regimen was not effective over 12 weeks.
Native PYY3-36 also posed two problems. Its appetite effect needed above-normal exposure, where nausea appeared (Degen et al., 2005). It is also cleared quickly, so early human studies relied on continuous infusions (Briere et al., 2026).
How is PYY being studied with semaglutide and other GLP-1 medicines?
Newer work tests long-acting PYY3-36 analogues designed to pair with GLP-1 drugs. Part of the rationale is that L cells release both hormones together. Vitrapep's semaglutide complete guide covers the GLP-1 medicine used in several of these trials.
Novo Nordisk's PYY1875 (NNC0165-1875) is a long-acting PYY3-36 analogue and selective Y2 agonist (Wulff et al., 2025). In a Phase 1 study of 88 men with overweight or obesity, single doses alone or with semaglutide were tolerated.
The Phase 2 trial first gave 96 adults with obesity semaglutide for 32 weeks, with average weight loss of 14.3%. Then 83 were randomized to PYY1875 or placebo as an add-on for 16 more weeks. With the main PYY1875 dose, weight fell a further 5.3%, compared with 3.1% on placebo. Only 20 of 47 participants in that group were on the target dose at the end. The authors called the efficacy modest and the treatment not well tolerated.
Eli Lilly's nisotirostide (LY3457263) is another PYY3-36 analogue. Its main chain has 34 amino acids with about 80% sequence identity to native PYY3-36. An attached fatty acid binds albumin, a blood protein, to extend its time in circulation (Briere et al., 2026).
Its Phase 1 study enrolled 65 healthy adults and adults with type 2 diabetes taking dulaglutide. After a single dose, weight change alone did not differ significantly from placebo. Added to dulaglutide, it produced up to 2.58 kg more weight loss than dulaglutide alone. A Phase 2 trial in type 2 diabetes on semaglutide or tirzepatide is recruiting. Vitrapep's guide to finding a peptide clinical trial explains how to read trial registry records.
What side effects have PYY studies reported?
The consistent signal across human PYY studies is gastrointestinal. In the 2005 infusion study, nausea and fullness were the most common side effects, especially at the highest rate (Degen et al., 2005). In Merck's 12-week trial, 27 of 46 participants (59%) in the higher-dose group stopped because of nausea and vomiting (Gantz et al., 2007).
In the PYY1875 Phase 2 trial, gastrointestinal events were common with the main dose. Earlier in that trial, 7 of 8 participants on the higher-dose regimen stopped because of gastrointestinal events (Wulff et al., 2025). With nisotirostide, nausea and vomiting were the most common events, rising with dose and mild to moderate (Briere et al., 2026).
The 2003 crossover study's abstract does not discuss adverse events, which is not the same as reporting none. Small, short studies cannot establish rare or long-term risks. Vitrapep's guide on how to evaluate peptide research explains these limits.
Is peptide YY an approved medicine?
No. A search of FDA's Drugs@FDA data on November 18, 2026 found no approved product containing PYY, PYY3-36 or nisotirostide. Both analogues described above remain investigational. Vitrapep's list of FDA-approved peptide medicines shows which related molecules are approved.
A research-use-only label does not make a compound legal or safe for people. See research peptides and human-use risks.
Frequently asked questions
What does PYY stand for?
Peptide YY. Y is the one-letter code for tyrosine, and human PYY begins with tyrosine and ends with a tyrosine amide.
Is peptide YY a peptide or a protein?
It is a peptide. Human PYY has 36 amino acids, and PYY3-36 has 34.
Where is PYY produced?
In L cells of the intestinal lining, mostly in the lower gut. The same cells make GLP-1.
Does PYY reduce appetite?
In short, controlled human studies, PYY3-36 infusions reduced food intake. One study found this significant only above normal after-meal levels.
Is PYY the same as GLP-1?
No. They are different hormones acting on different receptors, though L cells release them together.
Is there an FDA-approved PYY drug?
No. As of November 18, 2026, Drugs@FDA lists no PYY product. Analogues such as nisotirostide are investigational.
What to know now
- PYY is a 36-amino-acid gut hormone made by L cells, the same cells that make GLP-1.
- DPP-4 trims it to PYY3-36, a selective Y2 receptor agonist.
- Short human studies found lower food intake with PYY3-36; a 12-week drug trial found no significant weight loss.
- Nausea and vomiting have limited PYY drug development, and no PYY product is FDA-approved.
What we’re watching
- Results of the Phase 2 nisotirostide trial in type 2 diabetes on semaglutide or tirzepatide (NCT06897475); primary completion is estimated for May 2027.
- Whether newer long-acting PYY analogues can add weight loss to GLP-1 medicines with fewer gastrointestinal events.
- Research clarifying whether PYY3-36 has a natural role in human satiety at normal after-meal levels.